Pharmacogenetics of response to statins: where do we stand? (Q36089528)

12 August 2017

1 reference

title

Pharmacogenetics of response to statins: where do we stand? (English)

1 reference

12 August 2017

2

Eric Boerwinkle

0 references

author name string

Anke-Hilse Maitland-van der Zee

series ordinal

1

1 reference

12 August 2017

1 May 2005

1 reference

Current Atherosclerosis Reports

12 August 2017

1 reference

12 August 2017

7

1 reference

12 August 2017

204-208

1 reference

12 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-005-0007-3

12 August 2017

0 references

cites work

Pharmacogenomics. Interview by Clare Thompson

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-005-0007-3

Confounding and indication for treatment in evaluation of drug treatment for hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-005-0007-3

Assessment and control for confounding by indication in observational studies.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-005-0007-3

The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype

21 January 2018

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy

1 reference

12 December 2020

Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.

1 reference

12 December 2020

Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses--a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study.

1 reference

12 December 2020

Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism

1 reference

12 December 2020

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

1 reference

12 December 2020

The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqI

1 reference

12 December 2020

Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

1 reference

12 December 2020

Pharmacogenetic study of statin therapy and cholesterol reduction

1 reference

12 December 2020

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

1 reference

12 December 2020

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

1 reference

12 December 2020

A comprehensive review of genetic association studies

1 reference

12 December 2020

Determinants of disease and disability in the elderly: The Rotterdam elderly study

1 reference

12 December 2020

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

1 reference

12 December 2020

A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

1 reference

12 December 2020

The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study

1 reference

12 December 2020

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

1 reference

12 December 2020

A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.

1 reference

12 December 2020

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

1 reference

12 December 2020

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Identifying SNPs predictive of phenotype using random forests

1 reference

12 December 2020

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

1 reference

12 December 2020

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

1 reference

12 December 2020

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

1 reference

12 December 2020

Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia

1 reference

12 December 2020

Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy

1 reference

12 December 2020

Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia

1 reference

12 December 2020

The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction

1 reference

12 December 2020

Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy

1 reference

12 December 2020

Statins do more than just lower cholesterol

1 reference

12 December 2020

Trimming, weighting, and grouping SNPs in human case-control association studies

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy

1 reference

12 December 2020

Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.

1 reference

12 December 2020

Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

1 reference

12 December 2020

10.1007/S11883-005-0007-3

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15811254